Multiple myeloma, a complex and challenging hematologic malignancy, has seen remarkable advances in its treatment landscape. Standard care for transplant-eligible patients often involves quad therapy, blending immunomodulatory agents, proteasome inhibitors, anti-CD38 monoclonal antibodies, and corticosteroids. For frail or comorbid patients, triple therapy remains the mainstay. Hospitalized patients frequently benefit from CyBORD (cyclophosphamide, bortezomib, dexamethasone), and …
